Dr. Emily Stoulil, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 1376 Washington St, Eldora, IA 50627 Phone: 641-939-3831 Fax: 641-939-3922 |
Ronald C Neuerburg, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1376 Washington St, Eldora, IA 50627 Phone: 641-939-3831 Fax: 641-939-3922 |
Eldora Chiropractic Center Chiropractor Medicare: Medicare Enrolled Practice Location: 1376 Washington St, Eldora, IA 50627 Phone: 641-939-3831 |
Ronald C Neuerburg Dc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1376 Washington Street, Eldora, IA 50627 Phone: 641-939-3831 Fax: 641-939-3922 |
Dr. Zachary Stoulil, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1376 Washington St, Eldora, IA 50627 Phone: 641-939-3831 |
News Archive
Prime Minister Stephen Harper is being asked to act on the concerns of millions of Canadians with food allergies and celiac disease and listen to the advice of prominent national medical, consumer and health organizations and pass proposed federal food labelling regulations now. The Prime Minister is also encouraged to heed the results of a new public opinion poll showing close to 70% of Canadians want regulations to affect all pre-packaged food and beverages and not grant a special exemption for the beer industry.
Researchers at the UC San Diego School of Medicine and the Moores UCSD Cancer Center have new evidence that a type of immune system cell thought to be part of the first line of defense against breast cancer may also help promote its spread.
Scientists from Nanyang Technological University have discovered exactly how the malaria parasite is developing resistance towards the most important front-line drugs used to treat the disease.
UCLA researchers have discovered a new protein factor that contributes to a fibroblast cell's ability to migrate to a wound and participate in its healing process. The study's results could help scientists prevent cancer cells from using the same mechanisms to move throughout the body and spread.
Zogenix, Inc., a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee.
› Verified 9 days ago